NASDAQ NMS - GLOBAL MARKET · GTBP
-3.87% · -$0.2400 · Vol 31.8K
Market closed · last close 4:00 PM ET · price as of 19:25:19 ET
GT Biopharma Inc

GT Biopharma Inc

Biotechnology
$5.96
Card
Relationship Map

Follow $GTBP

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $GTBP by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
GTBP
GT Biopharma Inc
Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Lowest range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

20/ 100
Veridion Score
Lowest range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is GTBP moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading GTBP catalysts
About GT Biopharma Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
1
Country
US

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$6.20
Day high
$6.22
Day low
$5.80
Previous close
$6.20
52W high
$23.02
-74.10% from high
52W low
$5.24
4% of range
Market cap
$11.2M
EPS
$-47.5078
Beta
2.52
Shares out
1.8M
Volume
31.8K
0.34× rel vol
Avg volume
93.1K
VWAP
$5.97
Price history computed in-house
1W
-2.30%
1M
-0.33%
3M
-43.91%
1Y
-68.26%
YTD
-69.64%
SMA 50 $7.21 · below
SMA 200 $10.80 · below
52W position 4%

GTBP overview

Veridion Score
20
Registered · 2026-10-08
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around GTBP.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading GTBP Form 4 filings
Public disclosures

Congress activity in GTBP

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

GTBP contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GTBP in this window.
Lobbying spend

GTBP lobbying filings, year to date.

Registered lobbying filings matched to GT Biopharma Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for GTBP in this window.
Loading news for GTBP
Analyst ratings
Sovereign unlock shows live analyst consensus for GTBP.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.